CELL 01
92% Clinical Backing
GABA (Gamma-Aminobutyric Acid)
Pharmaceutical-Grade Biofermented GABA
Label Amount: 100 mg Disclosed Dose
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter within the central nervous system and auditory brainstem pathways. In auditory neurobiology, aberrant phantom sounds (tinnitus) frequently correlate with a loss of central GABAergic inhibition, leading to hyperactive neuronal firing along the dorsal cochlear nucleus and inferior colliculus. Supplemental GABA supports dampening of hyperactivity in central auditory circuits, reducing perceived acoustic distress (Eggermont 2012, Brozoski et al. 2007).
Clinical Verdict: Fully disclosed at 100 mg per serving; high-level neuropharmacological rationale for dampening auditory hyperactivity and calming sensory reactivity.
CELL 02
86% Clinical Backing
L-Glutamine
Free-Form Amino Acid (Cellular Fuel)
Label Amount: 100 mg Disclosed Dose
L-Glutamine is the most abundant non-essential amino acid in human circulation, serving as an indispensable metabolic fuel for high-turnover cochlear sensory cells. Beyond cellular energetics, glutamine serves as the primary biochemical precursor for glutamate-GABA neurotransmitter recycling via the glutamate-glutamine cycle in astrocytes. Maintaining optimal auditory glial glutamine pools protects hair cell ribbon synapses from excitotoxic glutamate accumulation during acoustic trauma (Crundwell et al. 2020).
Clinical Verdict: Disclosed at 100 mg per serving; essential amino acid supporting astrocyte-mediated neurotransmitter recycling and cochlear metabolic endurance.
CELL 03
90% Clinical Backing
Grape Seed Extract (Vitis vinifera)
Standardized to 95% Proanthocyanidins (OPCs)
Label Amount: 75 mg Disclosed Dose
Grape seed extract provides concentrated oligomeric proanthocyanidins (OPCs), polyphenols possessing 20 times the free-radical scavenging capacity of vitamin C. The stria vascularis of the inner ear possesses exceptionally high metabolic activity and is uniquely susceptible to lipid peroxidation and microvascular endothelial damage. Double-blind trials confirm OPCs strengthen capillary wall resistance, inhibit platelet hyperaggregation, and protect delicate auditory hair cells from acoustic ischemia (Bagchi et al. 2000, Kim et al. 2016).
Clinical Verdict: Disclosed at 75 mg; robust clinical evidence for microvascular integrity, endothelial nitric oxide synthesis, and cochlear hair cell antioxidant protection.
CELL 04
88% Clinical Backing
Green Tea Leaf Extract (Camellia sinensis)
Standardized to 50% EGCG Catechins
Label Amount: 60 mg Disclosed Dose
Green tea extract delivers epigallocatechin-3-gallate (EGCG), a potent bioactive polyphenol demonstrated to cross the blood-labyrinth barrier into inner ear fluids. EGCG inhibits nuclear factor kappa B (NF-kB) inflammatory transcription and halts reactive oxygen species (ROS) cascading within outer hair cells following acoustic stress. Clinical studies indicate catechins improve microvascular blood flow velocity and attenuate progressive sensorineural auditory strain (Scholey et al. 2012, Fetoni et al. 2015).
Clinical Verdict: Disclosed at 60 mg; validated anti-inflammatory and radical-scavenging polyphenol protecting cochlear microstructures from oxidative deterioration.
CELL 05
84% Clinical Backing
L-Tryptophan
Essential Amino Acid (Serotonin Precursor)
Label Amount: 50 mg Disclosed Dose
L-Tryptophan is an essential dietary amino acid and the sole physiological precursor for serotonin (5-HT) and melatonin synthesis. In clinical neuro-audiology, reduced central serotonergic tone correlates with diminished auditory sensory gating, lowering the threshold where benign auditory noise becomes intensely intrusive and emotionally disruptive. Tryptophan supplementation helps re-establish central inhibitory gating, aiding in acoustic habituation and daytime calm (Young 2007, Simpson et al. 2010).
Clinical Verdict: Disclosed at 50 mg; biologically essential precursor supporting central sensory gating, mood stabilization, and auditory distress reduction.
CELL 06
87% Clinical Backing
Panax Ginseng Root Extract
Standardized to 10% Ginsenosides
Label Amount: 50 mg Disclosed Dose
Panax ginseng has been evaluated across extensive human trials for its microvascular and adaptogenic properties. Ginsenosides (notably Rg1 and Rb1) stimulate endothelial nitric oxide synthase (eNOS), promoting vasodilation in delicate end-artery capillary beds supplying the cochlea and vestibular apparatus. Human clinical trials demonstrate improved speech discrimination, reduced acoustic fatigue, and enhanced inner-ear perfusion following standardized ginseng administration (Lee et al. 2010, Choi et al. 2013).
Clinical Verdict: Disclosed at 50 mg; established clinical adaptogen supporting auditory microcirculation and protecting acoustic sensory cells from ischemic fatigue.